{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:18:33Z","timestamp":1788365913178,"version":"build-2803163510"},"reference-count":46,"publisher":"American Chemical Society (ACS)","issue":"16","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccby_termsofuse.html"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Complex biotherapeutic modalities, such as antibody-drug conjugates (ADC), present significant challenges for the comprehensive bioanalytical characterization of their pharmacokinetics (PK) and catabolism in both preclinical and clinical settings. Thus, the bioanalytical strategy for ADCs must be designed to address the specific structural elements of the protein scaffold, linker, and warhead. A typical bioanalytical strategy for ADCs involves quantification of the Total ADC, Total IgG, and Free Warhead concentrations. Herein, we present bioanalytical characterization of the PK and catabolism of a novel ADC. MEDI3726 targets prostate-specific membrane antigen (PMSA) and is comprised of a humanized IgG1 antibody site-specifically conjugated to tesirine (SG3249). The MEDI3726 protein scaffold lacks interchain disulfide bonds and has an average drug to antibody ratio (DAR) of 2. Based on the structural characteristics of MEDI3726, an array of 4 bioanalytical assays detecting 6 different surrogate analyte classes representing at least 14 unique species was developed, validated, and employed in support of a first-in-human clinical trial (NCT02991911). MEDI3726 requires the combination of heavy-light chain structure and conjugated warhead to selectively deliver the warhead to the target cells. Therefore, both heavy-light chain dissociation and the deconjugation of the warhead will affect the activity of MEDI3726. The concentration\u2013time profiles of subjects dosed with MEDI3726 revealed catabolism of the protein scaffold manifested by the more rapid clearance of the Active ADC, while exhibiting minimal deconjugation of the pyrrolobenzodiazepine (PBD) warhead (SG3199).<\/jats:p>","DOI":"10.1021\/acs.analchem.0c01187","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T17:43:22Z","timestamp":1590601402000},"page":"11135-11144","source":"Crossref","is-referenced-by-count":29,"title":["Multifaceted Bioanalytical Methods for the Comprehensive\nPharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-Prostate-Specific\nMembrane Antigen Pyrrolobenzodiazepine Antibody\u2013Drug Conjugate"],"prefix":"10.1021","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-0856","authenticated-orcid":true,"given":"Yue","family":"Huang","sequence":"first","affiliation":[{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]},{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]},{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Del Nagro","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]},{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemal","family":"Balic","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]},{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"William R.","family":"Mylott","sequence":"additional","affiliation":[{"name":"PPD Laboratories 2244 Dabney Road , , ,","place":["Richmond, Virginia, United States, 23230"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omnia A.","family":"Ismaiel","sequence":"additional","affiliation":[{"name":"PPD Laboratories 2244 Dabney Road , , ,","place":["Richmond, Virginia, United States, 23230"]},{"name":"Zagazig University , , , ,","place":["Zagazig, Sharkia, Egypt, 44519"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ma","sequence":"additional","affiliation":[{"name":"PPD Laboratories 2244 Dabney Road , , ,","place":["Richmond, Virginia, United States, 23230"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morse","family":"Faria","sequence":"additional","affiliation":[{"name":"PPD Laboratories 2244 Dabney Road , , ,","place":["Richmond, Virginia, United States, 23230"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Wheeler","sequence":"additional","affiliation":[{"name":"PPD Laboratories 2244 Dabney Road , , ,","place":["Richmond, Virginia, United States, 23230"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moucun","family":"Yuan","sequence":"additional","affiliation":[{"name":"PPD Laboratories 2244 Dabney Road , , ,","place":["Richmond, Virginia, United States, 23230"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Waldron","sequence":"additional","affiliation":[{"name":"PPD Laboratories 2244 Dabney Road , , ,","place":["Richmond, Virginia, United States, 23230"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlking G.","family":"Peay","sequence":"additional","affiliation":[{"name":"PPD Laboratories 2244 Dabney Road , , ,","place":["Richmond, Virginia, United States, 23230"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego F.","family":"Cortes","sequence":"additional","affiliation":[{"name":"PPD Laboratories 2244 Dabney Road , , ,","place":["Richmond, Virginia, United States, 23230"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorin","family":"Roskos","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]},{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meina","family":"Liang","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]},{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]},{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-951X","authenticated-orcid":true,"given":"Anton I.","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]},{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]},{"name":"AstraZeneca , , , 121 Oyster Point Boulevard , , ,","place":["South San Francisco, California, United States, 94080"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"issue":"1","key":"2026090211331492500_cit1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics,\n2019","volume":"69","author":"Siegel","year":"2019","journal-title":"Ca-Cancer J. Clin."},{"issue":"9","key":"2026090211331492500_cit2","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1158\/1535-7163.MCT-11-0191","article-title":"In vitro and in vivo responses of\nadvanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody\nto prostate-specific membrane antigen","volume":"10","author":"Wang","year":"2011","journal-title":"Mol.\nCancer Ther."},{"issue":"8","key":"2026090211331492500_cit3","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1158\/1078-0432.CCR-05-2107","article-title":"Potent antitumor\nactivity of an auristatin-conjugated, fully human monoclonal antibody\nto prostate-specific membrane antigen","volume":"12","author":"Ma","year":"2006","journal-title":"Clin.\nCancer Res."},{"issue":"11","key":"2026090211331492500_cit4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00262-006-0131-0","article-title":"A recombinant PSMA-specific single-chain immunotoxin\nhas potent and selective toxicity against prostate cancer cells","volume":"55","author":"Wolf","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"2026090211331492500_cit5","first-page":"1807","article-title":"Expression\nof the prostate-specific membrane antigen","volume":"54","author":"Israeli","year":"1994","journal-title":"Cancer\nRes."},{"issue":"24","key":"2026090211331492500_cit6","first-page":"6306","article-title":"Sensitive nested reverse transcription\npolymerase chain reaction detection of circulating prostatic tumor\ncells: comparison of prostate-specific membrane antigen and prostate-specific\nantigen-based assays","volume":"54","author":"Israeli","year":"1994","journal-title":"Cancer Res."},{"issue":"5","key":"2026090211331492500_cit7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ijc.2910620511","article-title":"Detection\nand characterization of\nthe prostate-specific membrane antigen (PSMA) in tissue extracts and\nbody fluids","volume":"62","author":"Trover","year":"1995","journal-title":"Int. J. Cancer"},{"issue":"11","key":"2026090211331492500_cit8","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11&lt;2259::AID-CNCR5&gt;3.0.CO;2-T","article-title":"Current\nevaluation of the tissue localization and diagnostic utility of prostate\nspecific membrane antigen","volume":"83","author":"Murphy","year":"1998","journal-title":"Cancer"},{"issue":"4","key":"2026090211331492500_cit9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","article-title":"Prostate-specific\nmembrane antigen expression is greatest in prostate adenocarcinoma\nand lymph node metastases","volume":"52","author":"Sweat","year":"1998","journal-title":"Urology"},{"issue":"1","key":"2026090211331492500_cit10","first-page":"2","article-title":"Prostate-specific\nmembrane antigen:\ncurrent and future utility","volume":"16","author":"Gregorakis","year":"1998","journal-title":"Semin. Urol. Oncol."},{"issue":"4","key":"2026090211331492500_cit11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/sj.pcan.4500233","article-title":"A novel\nmonoclonal antibody 107\u20131A4\nwith high prostate specificity: generation, characterization of antigen\nexpression, and targeting of human prostate cancer xenografts","volume":"1","author":"Brown","year":"1998","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"4","key":"2026090211331492500_cit12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1023\/A:1006308826967","article-title":"Prostate-specific\nmembrane antigen (PSMA)-specific monoclonal antibodies in the treatment\nof prostate and other cancers","volume":"18","author":"Gong","year":"1999","journal-title":"Cancer Metastasis\nRev."},{"issue":"5","key":"2026090211331492500_cit13","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0093-7754(03)00358-0","article-title":"Targeted systemic therapy of prostate\ncancer with a monoclonal antibody to prostate-specific membrane antigen","volume":"30","author":"Bander","year":"2003","journal-title":"Semin. Oncol."},{"issue":"5","key":"2026090211331492500_cit14","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1097\/01.ju.0000091655.77601.0c","article-title":"Targeting\nmetastatic prostate cancer with radiolabeled\nmonoclonal antibody J591 to the extracellular domain of prostate specific\nmembrane antigen","volume":"170","author":"Bander","year":"2003","journal-title":"J. Urol."},{"issue":"1","key":"2026090211331492500_cit15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/sj.pcan.4500543","article-title":"In vitro\nand preclinical targeted alpha therapy of human prostate cancer with\nBi-213 labeled J591 antibody against the prostate specific membrane\nantigen","volume":"5","author":"Li","year":"2002","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"3","key":"2026090211331492500_cit16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1517\/13543784.10.3.511","article-title":"PSMA specific\nantibodies and their diagnostic and therapeutic use","volume":"10","author":"Holmes","year":"2001","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"18","key":"2026090211331492500_cit17","first-page":"4055","article-title":"Constitutive and\nantibody-induced internalization of prostate-specific membrane antigen","volume":"58","author":"Liu","year":"1998","journal-title":"Cancer Res."},{"issue":"6","key":"2026090211331492500_cit18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/pros.23765","article-title":"Phase 1 study of PSMA ADC, an antibody-drug\nconjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory\nprostate cancer","volume":"79","author":"Petrylak","year":"2019","journal-title":"Prostate"},{"issue":"3","key":"2026090211331492500_cit19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2967\/jnumed.117.196279","article-title":"Characterization\nof Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based\nAnti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing\nTumors","volume":"59","author":"Lutje","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"3","key":"2026090211331492500_cit20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/pros.23124","article-title":"Addition of PSMA ADC\nto enzalutamide therapy significantly improves\nsurvival in in vivo model of castration resistant prostate cancer","volume":"76","author":"DiPippo","year":"2016","journal-title":"Prostate"},{"issue":"7","key":"2026090211331492500_cit21","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1021\/acs.bioconjchem.6b00222","article-title":"Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted\nTheranostics","volume":"27","author":"Kumar","year":"2016","journal-title":"Bioconjugate Chem."},{"issue":"12","key":"2026090211331492500_cit22","doi-asserted-by":"publisher","first-page":"530.e15","DOI":"10.1016\/j.urolonc.2016.07.005","article-title":"Phase 1\/2 multiple\nascending dose trial of the prostate-specific membrane antigen-targeted\nantibody drug conjugate MLN2704 in metastatic castration-resistant\nprostate cancer","volume":"34","author":"Milowsky","year":"2016","journal-title":"Urol. Oncol."},{"key":"2026090211331492500_cit23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-62703-541-5_1","article-title":"Antibody-drug conjugate (ADC) clinical\npipeline: a review","volume":"1045","author":"Sassoon","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"2026090211331492500_cit24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-62703-541-5_4","article-title":"Antibody-drug conjugate\npayloads","volume":"1045","author":"Anderl","year":"2013","journal-title":"Methods Mol. Biol."},{"issue":"20","key":"2026090211331492500_cit25","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug\nconjugates of calicheamicin derivative: gemtuzumab ozogamicin and\ninotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"2026090211331492500_cit26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1517\/13543784.2011.641532","article-title":"Brentuximab\nVedotin (SGN-35), an antibody-drug conjugate for the treatment of\nCD30-positive malignancies","volume":"21","author":"Gualberto","year":"2012","journal-title":"Expert Opin. Invest.\nDrugs"},{"issue":"10","key":"2026090211331492500_cit27","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab\nVedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent\nTherapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"issue":"3","key":"2026090211331492500_cit28","first-page":"350","article-title":"Trastuzumab\nemtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic\nbreast cancer","volume":"12","author":"Niculescu-Duvaz","year":"2010","journal-title":"Curr. Opin. Mol. Ther."},{"key":"2026090211331492500_cit29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40265-019-1053-4","article-title":"Polatuzumab\nVedotin: First Global Approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"issue":"6","key":"2026090211331492500_cit30","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab\nderuxtecan (DS-8201a) in patients with advanced HER2-positive breast\ncancer previously treated with trastuzumab emtansine: a dose-expansion,\nphase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol."},{"issue":"6","key":"2026090211331492500_cit31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","article-title":"Trastuzumab\nderuxtecan (DS-8201a)\nin patients with advanced HER2-positive gastric cancer: a dose-expansion,\nphase 1 study","volume":"20","author":"Shitara","year":"2019","journal-title":"Lancet Oncol."},{"key":"2026090211331492500_cit32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/EDBK_281103","article-title":"The Evolution\nof Antibody-Drug Conjugates: A Positive Inflexion Point","volume":"40","author":"Tolcher","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"8","key":"2026090211331492500_cit33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab\nGovitecan-hziy\nin Refractory Metastatic Triple-Negative Breast Cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"2026090211331492500_cit34","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","article-title":"ADCT-301, a Pyrrolobenzodiazepine\n(PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing\nHematological Malignancies","volume":"15","author":"Flynn","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"2026090211331492500_cit35","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402,\na PBD dimer-containing antibody drug conjugate targeting CD19-expressing\nmalignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2026090211331492500_cit36","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/1535-7163.MCT-17-0982","article-title":"Antitumor\nActivity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug\nConjugate Targeting PSMA, in Preclinical Models of Prostate Cancer","volume":"17","author":"Cho","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"2026090211331492500_cit37","doi-asserted-by":"publisher","first-page":"104429","DOI":"10.1016\/j.yrtph.2019.104429","article-title":"An FDA oncology\nanalysis of toxicities associated with PBD-containing antibody-drug\nconjugates","volume":"107","author":"Saber","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"4","key":"2026090211331492500_cit38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/antib7040041","article-title":"ADME Considerations\nand Bioanalytical\nStrategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates","volume":"7","author":"Mou","year":"2018","journal-title":"Antibodies"},{"issue":"11","key":"2026090211331492500_cit39","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1021\/acsmedchemlett.6b00062","article-title":"Design\nand Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine\nDimer Payload","volume":"7","author":"Tiberghien","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"issue":"6_suppl","key":"2026090211331492500_cit40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1200\/JCO.2020.38.6_suppl.99","volume":"38","author":"De Bono","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"2026090211331492500_cit41","unstructured":"A Phase 1\/1b Study of MEDI3726 in Adults Subjects\nWith Metastatic\nCastration Resistant Prostate Cancer, https:\/\/ClinicalTrials.gov\/show\/NCT02991911."},{"issue":"8","key":"2026090211331492500_cit42","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1517\/17425255.2014.925878","article-title":"Assessment\nof the metabolism of therapeutic\nproteins and antibodies","volume":"10","author":"Ezan","year":"2014","journal-title":"Expert Opin. Drug Metab.\nToxicol."},{"issue":"2","key":"2026090211331492500_cit43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4155\/bio.11.304","article-title":"Metabolism of biologics: biotherapeutic\nproteins","volume":"4","author":"Hamuro","year":"2012","journal-title":"Bioanalysis"},{"issue":"2","key":"2026090211331492500_cit44","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.pep.2013.02.016","article-title":"Design, production,\nand characterization of a single-chain variable fragment (ScFv) derived\nfrom the prostate specific membrane antigen (PSMA) monoclonal antibody\nJ591","volume":"89","author":"Parker","year":"2013","journal-title":"Protein Expression Purif."},{"issue":"1","key":"2026090211331492500_cit45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","article-title":"Considerations for\nthe Design of Antibody-Based Therapeutics","volume":"109","author":"Goulet","year":"2020","journal-title":"J.\nPharm. Sci."},{"issue":"3","key":"2026090211331492500_cit46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mas.21540","article-title":"The Skyline ecosystem: Informatics\nfor quantitative\nmass spectrometry proteomics","volume":"39","author":"Pino","year":"2020","journal-title":"Mass Spectrom.\nRev."}],"container-title":["Analytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.analchem.0c01187","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/ancham\/article-pdf\/92\/16\/11135\/66920255\/acs.analchem.0c01187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/ancham\/article-pdf\/92\/16\/11135\/66920255\/acs.analchem.0c01187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:33:21Z","timestamp":1788363201000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/ancham\/article\/92\/16\/11135\/827040\/Multifaceted-Bioanalytical-Methods-for-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":46,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2020,5,27]]},"published-print":{"date-parts":[[2020,8,18]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.analchem.0c01187","relation":{},"ISSN":["0003-2700","1520-6882"],"issn-type":[{"value":"0003-2700","type":"print"},{"value":"1520-6882","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]}}}